Inogen, Inc. INGN announced preliminary revenues for the fourth quarter and full year 2024 on Monday. Following the robust ...

In October this year, the company commenced the US market release of the ‘Inogen Rove 4 Portable Oxygen Concentrator’. The Rove 4 incorporates the company’s patented pulse-dose Intelligent ...

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Inogen (INGN – Research Report) yesterday and set a price target of ...

Needham analyst Michael Matson has maintained their neutral stance on INGN stock, giving a Hold rating yesterday.Stay Ahead of the ...

Recent Development for INGN In October, INGN announced that it had commenced the U.S. market release of the Inogen Rove 4 Portable Oxygen Concentrator. The Rove 4 utilizes Inogen’s patented ...

Inogen, Inc. (NASDAQ: INGN) is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter ...

INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device. The latest announcement is out from Inogen ( (INGN) ). Inogen, Inc. announced that it has received FDA 510(k) clearance for ...

Inogen estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 ...

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid second-quarter 2024 ...